Karl Keegan

Karl David Keegan is currently a Non-Executive Director at Novai Ltd. and a Life Science Analyst at Singer Capital Markets Securities Ltd. since 2022.
Former roles include Chief Executive Officer & Director at Hox Therapeutics Ltd., Independent Non-Executive Director at Conroy Gold & Natural Resources Plc from 2017 to 2018, Managing Director & Head-Research Division at Canaccord Adams Ltd. in 2009, CFO & Director-Corporate Development at Shield Therapeutics Plc from 2017 to 2018, Senior Independent Non-Executive Director at Nuformix Plc from 2020 to 2021, Biotechnology Analyst at UBS AG, Global Sector Head-Life Sciences Research at Canaccord Genuity Group, Inc., Chief Corporate Development Officer at Vectura Group Ltd. from 2014 to 2016, Chief Financial Officer at e-Therapeutics Plc in 2021, Chief Financial Officer at Minster Pharmaceuticals Plc in 2010, CFO & Member-Management Board at Pharming Group NV from 2010 to 2012, Biotechnology Analyst at Dresdner Kleinwort Benson Equity, and Biotechnology Analyst at Banc of America Specialist, Inc. Education includes undergraduate degree from University College Dublin in 1988, graduate and doctorate degrees from the University of Cambridge, and a graduate degree from London Business School.